We analysed the antigenic properties of human cytomegalovirus (CMV) glycoprotein B (gB) by constructing a set of deletion derivatives lacking different portions of the carboxy terminus and reacting them with a panel of monoclonal antibodies with neutralizing activity. We found that two novel antigenic domains that bind neutralizing antibodies were assembled on truncated forms ofgB, one in the aminoterminal half and one that spans the midregion of the molecule. Assembly of the conformation-dependent epitopes occurred independently of residues in the carboxy-terminal half of the molecule and did not depend on proteolytic cleavage of the molecule between amino acids 460 and 461. Ten antibodies recognized a derivative with 447 amino-terminal residues; their failure to recognize a derivative 411 residues long suggested that the amino acids required for assembly of these epitopes either were incorrectly folded, or had been totally or partially deleted in this derivative. Epitopes for three antibodies with complementindependent neutralizing activity were assembled when amino acids from the midregion of gB between residues 447 and 476 were present. Two other antigenic domains were formed by the addition of residues 476 to 618 and 619 to 645 from the carboxy-terminal half of gB. Our results underscore the importance of conformation in the antigenic structure and functional properties of both the amino-and carboxy-terminal portions of gB.
Introduction
Human cytomegalovirus (CMV) is a pathogen that causes significant morbidity and mortality in immunocompromised patients, including organ transplant recipients (Meyers et al., 1986; Singh et al., 1988) and congenitally infected newborns (Pass et al., 1980; Stagno et al., 1983) . Among those at risk from life-threatening CMV pneumonia and CMV chorioretinitis are patients with AIDS (Drew, 1988; Jacobson & MiUs, 1988; Pepose, 1989) . CMV infections elicit neutralizing antibodies that react with the viral glycoproteins in infected cells, particularly with a major virion envelope glycoprotein (Britt & Vugler, 1990; Pereira et al., 1982a Pereira et al., , 1983 Pereira et al., , 1992 Rasmussen et al., 1991) that has been designated glycoprotein B (gB) on the basis of sequence similarity with herpes simplex virus 1 (HSV-1) glycoprotein B (Chee et al., 1990; Cranage et al., 1986; Pellett et al., 1985) .
CMV gB is a major component of the virion envelope (Farrar & Greenaway, 1986) . It is highly immunogenic, t Present address: University of Valencia, Faculty of Medicine, Valencia, Spain. inducing neutralizing antibodies in infected patients and in animals immunized with the glycoprotein (Britt et al., 1988; Gonczol et al., 1986; Rasmussen et al., 1985) . CMV gB is made as a single polypeptide chain of approximately 120K which undergoes glycosylation and cleavage between residues 460 and 461 during transport through the exocytic pathway (Pereira et aL, 1984; Radsak et al., 1990; Rasmussen et al., 1988 , Spaete et al., 1988 . Cleavage of gB occurs in the Golgi compartment, and the specificity of the calcium-dependent protease for the target site is dependent on basic amino acids at or near this site (Spaete et al., 1990) . The gB heterodimer is composed of the amino-and carboxy-terminal fragments, which remain disulphide-bonded (Britt, 1984) and are anchored in the membranes of infected cells by the hydrophobic transmembrane sequence (Spaete et al., 1988) . The amino-terminal portion, having 15 N-glycosylation sites, is heavily modified and is approximately 110K; the carboxy-terminal portion, having five glycosylation sites, is approximately 58.5K (Meyer et al., 1990; Pereira et al., 1984; Rasmussen et al., 1988) . Nucleotide sequence analyses ofgB genes from CMV strains AD169 and Towne show sequence variation at the extreme amino terminus between residues 28 and 67 (Cranage et 0001-1092 © 1992 SGM I. Qadri and others al., 1986; Spaete et al., 1988) . Analysis of several clinical strains also showed sequence variability in other regions of the molecule, including residues 440 to 460 (Chou, 1992; Chou & Dennison, 1991) .
Our studies on CMV gB have focused on mapping its antigenic and functional regions using a panel of monoclonal antibodies (MAbs). Analysis of the epitopes in the extreme amino terminus of gB revealed a region of continuous amino acids that binds several antibodies, including one with complement-dependent neutralizing activity (Basgoz et al., 1992; Meyer et al., 1992; Pereira et al., 1991) . In the present study, we made a set of deletion constructs in the CMV (AD169) gB gene encoding derivatives that lacked carboxy-terminal sequences of various lengths. Epitopes assembled on these derivatives were identified by transiently expressing the products in COS-1 cells and detecting them by immunofluorescence, and in some instances by immunoprecipitation, using neutralizing antibodies to gB. We found four conformation-dependent regions on gB that bind neutralizing antibodies and identified the amino acids required for assembly of discontinuous epitopes in these regions. Our studies show that the amino-terminal half of gB between residues 411 and 447 is required to assemble an antigenic region recognized by antibodies with complementindependent and -dependent neutralizing activity. Assembly of the epitopes in this region is independent of the carboxy-terminal half of the molecule. We also identified the amino acids required to assemble epitopes in the midregion of gB that span the proteolytic cleavage site. Lastly, we more precisely defined the amino acids required to assemble epitopes in the carboxy-terminal half of gB that had been identified in an earlier study .
Methods

Construction of deletion derivatives in CMV (AD169) gB.
A panel of deletion derivatives of CMV (AD169) gB was constructed. BamHI fragment T containing the gB gene ofCMV (AD169) was excised from cosmid 7091 (Fleckenstein et al., 1982) and cloned into the BamHI site of pUC18. The EagI fragment (3125 bp) encoding gB was cloned into the SmaI site of the eukaryotic expression vector pMT2 (Wong et al., 1985) and designated pMTgB. A derivative, pMT3, was constructed by inserting a synthetic linker, SpeI, with stop codons in all three frames at the blunt-ended EcoRI site. Subfragments expressing gB of various lengths were then cloned into this plasmid at the appropriate restriction sites. The deletion constructs were obtained by using convenient restriction endonuclease sites within the gB gene. Plasmids p258, p411, p447 and p476 were obtained by excising the BgllI and blunt-ended BssHII, NdeI, ClaI and ApaLI fragments, respectively, from pMTgB and then cloning them into the BgllI and Sinai restriction sites of pMT3. Plasmids p618, p645 and p687 were obtained by excising the (Spaete et al., 1988) . The box indicates the transmembrane region.
first cloned into the EcoRI site of pUC18 and a SpeI linker containing stop codons in all three frames was added to the Bali site of the gB sequence. This subfragment, which contained a stop codon at residue 760, was cloned into the EcoRI site of the EagI fragment in the correct orientation.
Cells and medium. COS-1 cells were obtained from the American Type Culture Collection and were grown in Dulbecco's modified Eagle's minimum essential medium, supplemented with 10~ foetal bovine serum.
MAbs. The properties of the panel of MAbs to CMV (AD169) gB produced in this laboratory and used in this study have been reported Pereira et al., 1982b Pereira et al., , 1984 . The mechanism of neutralization by these antibodies will be described elsewhere (D. Navarro et at., unpublished data). Cells were fixed in acetone and stained with MAbs after 48 h as previously described (Pereira et al., 1989) . The pool of MAbs used for immunofluorescence reactions consisted of CH45-1, CH86-3, CH408-1 and CH386-3 which recognize continuous epitopes mapping in domain DClv (Table 2) .
DNA transfections. Plasmid DNAs (10 to 20 ktg/106 cells) were precipitated on COS-I cells using calcium phosphate. Cells were exposed to DNA precipitates in medium containing chloroquine (100 ~tM) for 5 h, then rinsed and fresh medium was added.
Radiolabelling, immunoprecipitation and PAGE. Plasmid DNAs were precipitated on COS-1 ceils as described above and were labelled with [35S]methionine (5 ~tCi/ml; DuPont New England Nuclear) from 36 to 48 h post-transfection. The cells and culture medium were extracted with 1 ~ sodium deoxycholate, 1 ~ Nonidet P-40 and 0.1 ~ SDS. The extracts were reacted with the antibodies and the precipitates formed were eluted in SDS, boiled and electrophoresed in a denaturing polyacrylamide gel (9~ polyacrylamide cross-linked with diallyltartardiamide).
Results
Transient expression of deletion constructs of CMV gB
The structure of the deletion derivatives in the gB gene of CMV (AD169) (Table 2) . (Table 2) . Lane M, Mr markers, gB bands contained in the precipitates are indicated by dots.
spanned the amino-terminal half of gB expressed the residues from positions I to 258, 411 and 447. The longer derivatives expressed the residues from positions 1 to 476, 618, 645, 687 and 760 in the carboxy-terminal half beyond the cleavage site between amino acids 460 and 461. In the first series of experiments, the derivatives of gB were expressed by transfecting COS-1 cells with plasmid DNAs containing the deletion constructs. Expression of the truncated glycoproteins was first monitored by immunofluorescence with a pool of MAbs to continuous epitopes mapping at the extreme amino terminus within residues 28 to 67 (Basgoz et al., 1992; Pereira et al., 1991) . Each construct expressed a protein reactive with the antibody pool at levels approximately equivalent to that detected in cells transfected with the intact gB gene (Fig. 2) . In general, the staining pattern exhibited by these mutated proteins did not differ significantly from the pattern observed in cells expressing wild-type gB. The exception was gB-(1-411) (Fig. 2c) , which showed a reticular distribution when compared with gB and the other derivatives.
To determine whether the actual sizes of the proteins agreed with estimates of their size based on the number of residues contained in the derivatives, immunoprecipitation reactions were performed with the pool of antibodies to the extreme amino terminus of gB. Transfected COS-1 cells were radiolabelled and precipitated as described in Methods. Fig. 3 compares the electrophoretic mobilities of the mutated forms with that of intact gB. Analysis of the precipitates formed from the cell extracts showed that the truncated products migrated more slowly than the predicted size and appeared to be modified by the addition of sugars. The shift in mobility for each product depended on the number of N-glycosylation sites retained after truncation of the molecule, based on the predicted Asn-X-Ser/Thr consensus sequences in the AD169 gB gene (Cranage et al., 1986) . The apparent Mr of the derivatives was as follows: gB-(1-258), 46K; gB-(1-411), 72K; gB-(1-447), 82K; gB-(1-476), 91K; gB-(1-618), 101K; gB-(1-645), 106K; gB-(1-687), 110K; gB-(1-760), 116K. Analysis of precipitates formed after the reaction of antibodies with the culture medium indicated that the truncated forms of gB were poorly released from cells (data not shown).
We had noted previously that trace amounts of cleaved gB were generated in transient expression of the CMV L Qadri and others CH177-3, CH253-1, CH358-5, ---
CH244-4, CH130-9, CH143-13
CH51-4, CHl14-5, CH409-2 ..... + + + * Numbers indicate the length (no. of amino acids) of CMV (AD169) amino-terminal derivatives. t Immunofluorescence reactions were weak but reproducible with CMV gB-(1-447).
strain Towne gB gene . In the present study, the carboxy-terminal cleavage fragments expected to be generated from intact gB were again barely detectable. Cleavage of the longer derivatives gB-(1-645), gB-(1-687) and gB-(1-760) was not detected even though the size of these fragments would have been within the separation limits of this gel and others of higher acrylamide concentration. Insofar as intact gB and the longer derivatives are not cleaved in COS-1 cells (Fig. 3 ), it appears that this cell type does not contain significant amounts of the calcium-dependent protease found in CHO cells stably expressing a truncated form of the gB gene (Spaete et al., 1990) . We have reported that the panel of MAbs to CMV gB immunoprecipitates both the intact form of gB and the faster migrating cleavage products (Pereira & Hoffman, 1986; Pereira et al., 1984) ; thus cleavage does not affect the conformation of these epitopes. In order to confirm that uncleaved gB molecules do not differ significantly in conformation from cleaved forms, a CHO cell line expressing the mutant CMV gB pXgB24clv4, which contains three altered residues near the cleavage site (Spaete et al., 1990) , was reacted with a subset of MAbs to domains D1, D2a, D2b and D3 (Table 2 ) spanning the length of the molecule (D. Spaete, unpublished observations). It was found that the antibodies recognized the uncleaved derivative ofgB, indicating that lack of cleavage does not affect these epitopes.
MAbs recognize epitopes assembled by truncated derivatives of gB
In the next series of experiments, we located the amino acids required to assemble the conformation-dependent neutralizing epitopes on gB by reacting each truncated glycoprotein in immunofluorescence tests with the individual MAbs. Results of these experiments (Table 1) are summarized as follows. (i) The shortest glycoproteins, gB-(1-258) and gB-(1-411), did not assemble any of the discontinuous epitopes detected by the antibody panel. However, gB-(1-258) contained the continuous neutralizing epitope recognized by antibody CH408-1, which had been shown previously to map in domain DC 1 v in the extreme amino terminus (Basgoz et al., 1992; Meyer et al., 1992; Pereira et al., 1991) .
(ii) In contrast to the results obtained with gB-(1-411), analysis of the next longer form gB-(1-447), comprising almost the entire amino-terminal half of gB, showed that 10 conformationdependent epitopes were present. Of these epitopes, five (CH177-3, CH253-1, CH358-5, CH382-2 and CH388-4) had complement-independent neutralizing activity and five had complement-dependent activity (Table 2 ) (D. Navarro et al., unpublished data). Four antibodies (CH87-1, CH92-1, CH105-7 and CHII2-1) reacted weakly but reproducibly with gB-(1-447), indicating that their epitopes, grouped here in domain D1, may be only partially assembled on this form of the molecule. The neutralizing domain assembled when amino acids 411 to 447 are present, designated domain D1, is the first discontinuous antigenic region to be identified in the amino-terminal half of CMV gB. (iii) Three additional discontinuous epitopes, recognized by neutralizing antibodies CH244-4, CH130-9 and CH143-13, were assembled on gB-(1-476). These epitopes were grouped into domain D2a and are assembled when residues 447 to 476 are present. (iv) Six more discontinuous epitopes, recognized by antibodies CH424-1, CH432-1, CH434-1, CH436-1, CH442-1 and CH446-2, were expressed on gB-(1-618). These epitopes were grouped into domain D2b, which is assembled by the addition of residues 476 to 618 in the carboxy-terminal half of gB. (v) gB-(1-645) contained epitopes for three neutralizing antibodies, 
CHl12-1 -D2a, midregion: 447 to 476 M-11 CH244-4 + M-12 CH130-9 + M-13 CH143-13 + D2b, carboxy-terminal half: 476 to 618
CH436-1 + D3, carboxy-terminal half: 618 to 645 C-7 CH51-4 -C-8 CH114-5 -C-9 CH409-2 -DC2, intracellular: 716 to 906 I-1 CH158-2 I-2 CH216-2 I-3 CH380-4 1-4 CH381-1 1-5 CH385-3 1-6 CH402-5 1-7 CH410-3 DC3, intraceUular: 833 to 898 I-8 CH405-1 1-9 CH421-5 1-10 CH28-2 , 1992; Meyer et al., 1992; Pereira et al., 1991) . :~ (Kniess et al., 1991; Liu et al., 1991; Utz et al., 1989; Spaete et al., 1988) .
CH51-4, CHl14-5 and CH409-2, shown in an earlier study to be assembled when residues 619 to 680 are present . This result indicated that the residues required for assembly of these discontinuous epitopes are located between amino acids 619 and 645 in the carboxy terminus, in a domain which we have designated D3. (vi) gB-(1-687) and gB-(1-760) expressed all of the discontinuous epitopes contained in gB-(1-645), but failed to express the continuous epitopes in domains DC2 and DC3, which had been previously mapped in the intracellular carboxy terminus (Basgoz et al., 1992; Pereira et al., 1991) .
Discontinuous epitopes assembled by residues in the amino-terminal half and midregion of gB
Some of the epitopes found in the present study to assemble in domains D1 and D2 were reported to require residues closer to the carboxy terminus of gB for their formation in an earlier study in which we used two deletion constructs of CMV strain Towne gB expressing 618 and 680 amino acids . Immunofluorescence analysis of the shorter AD 169 gB constructs now indicated that these epitopes are formed by assembling residues closer to the amino terminus of the molecule. To confirm the location of these epitopes in the amino-terminal half of gB, we performed two immunoprecipitation experiments. In the first experiment, we reacted selected antibodies from domain D 1 by immunoprecipitation with the short derivatives gB-(1-411) and gB-(1-447) (Fig. 4) . Antibody CH408-1, recognizing the amino-terminal domain DClv, and antibody CH442-1, recognizing domain D2b between residues 476 and 618, served as positive and negative control antibodies, respectively. We found that antibodies CH177-3 and CH382-2, which had and had not reacted with the 618-residue Towne construct respectively, precipitated gB-(1-447) but failed to recognize the shorter mutant gB-(1-41t), confirming the immunofluorescence experiments showing that these epitopes map in the aminoterminal half of gB. As expected, antibody CH408-1 recognized both of the AD169 gB derivatives and antibody CH442-1 failed to react with either. In the second experiment, several of the antibodies that had failed to react by immunofluorescence with the 618-residue Towne gB construct , but did react by immunofluorescence with the AD169 construct of the same length (Table 1) , were tested in immunoprecipitation reactions with this AD169 construct. Of these antibodies, CH382-2, CH395-1, CH105-7 and CH112-1 recognized antigenic region D1, CH244-4 and CH130-9 recognized region D2a, and CH434-1, CH436-1 and CH446-2 recognized region D2b. We also included three antibodies (CH409-2, CH51-4 and CHl14-5) that were non-reactive by immunofluorescence with both the Towne and AD169 constructs, and one antibody (CH412-2) to domain DC l v as a positive control (Pereira et al., 1991) . The results obtained by immunoprecipitation (Fig. 5 ) agreed with the results obtained by immunofluorescence with three exceptions. Antibodies CH105-7 and CHll2-1, which were positive by immunofluorescence, failed to precipitate the derivative. In this case, it is likely that the epitopes present in the native form were lost from the detergent-solubilized derivative. In contrast, CH244-4, which was negative in immunofluorescence tests, reacted with the mutant construct by immunoprecipiration, suggesting that this epitope was either not properly assembled or not accessible to the antibody on the folded form of the derivative. It is possible that (Spaete et al., 1988) . The shaded box designates the hydrophobic transmembrane domain (Cranage et aL, 1986) . Immunodominant neutralizing domain D2b and neutralizing domain D3 contain antigenic sites mapped by other laboratories (Kniess et al., 1991 ; Liu et al., 1991 ; Spaete et aL, 1988; U tz et al., 1989) .
different results obtained with the Towne construct in the previous study were due to small differences in the amino acid sequence between the strains; however, this seems unlikely since the antibodies that failed to react with the Towne derivative nevertheless recognized epitopes shared by the intact gB of both strains AD169 and Towne. The most likely explanation is that the differences in reactivities with the Towne construct may have resulted from a small spontaneous inframe internal deletion generated during the construction of this mutant gB. Particularly relevant to the folding of the truncated forms of gB are four cysteine residues mapping between amino acids 411 and 618. A mutation that altered a cysteine residue might have led to mispairing of the cysteines, causing formation of mismatched disulphide bonds, partial malfolding of the molecule and loss of selected epitopes. The detailed analysis of the set of eight deletion derivatives in the AD169 gB gene that we have now completed enables us to locate correctly the amino acids required to assemble the conformation-dependent epitopes in the various antigenic regions of the molecule.
Discussion
In this study, we generated from the CMV gB gene a set of deletion constructs that lacked different lengths of the sequences specifying the carboxy terminus, in order to locate residues that confer reactivity with our panel of MAbs. Table 2 summarizes our findings to date regarding the antigenic regions of CMV (AD169) gB, which have been analysed by identifying amino acids required to assemble the epitopes recognized by neutralizing antibodies. The locations of these regions are summarized in a schematic diagram (Fig. 6) . We have divided the gB molecule into four antigenic regions: the amino (N) terminus residues from 28 to 67, the midregion (M) residues from 411 to 476, the carboxy (C) terminus residues from 476 to 645, and the intracellular (I) residues from 716 to 906. Epitopes of antibodies recognizing each antigenic region have been grouped in Table 2 by their location in the gB molecule, e.g. N-I, M-l, etc. We have identified three regions of continuous epitopes: DClv, a neutralizing domain in the amino terminus region which contains strain-specific epitopes, and DC2 and DC3, located in the intracellular region of the molecule (Basgoz et al., 1992; Pereira et al., 1991) . Our work and that of others (Meyer et al., 1990) has shown that nucleotide sequence differences in the extreme amino terminus of gB specified by strains AD169 and Towne (Spaete et al., 1988) affect their antigenic properties. Both conserved and variable antigenic sites are contained in the region encompassing domain DClv (Meyer et al., 1992) . Other investigators have identified continuous neutralizing epitopes mapping between residues 589 and 645 (Kniess et al., 1991) and between 608 and 625 (Utz et al., 1989) . Discontinuous neutralizing epitopes are assembled in four domains, D1, D2a and D2b, and D3. Domain D1, one of two novel conformation-dependent domains identified in this study, is assembled in part by the folding of residues 411 to 447 in the amino-terminal half of gB. Domain D2a, the second novel domain, is assembled in the midregion by residues 447 to 476, spanning the cleavage site. Domain D2b, also in the midregion, is assembled by amino acids 476 to 618, and domain D3 by amino acids 619 to 645 in the carboxy-terminal half of the molecule. The antigenic region designated AD-1 by others (Kniess et al., 1991) , which contains a continuous epitope mapping between residues 589 and 645, partially overlaps domains D2 and D3. In locating the recognition sites of a large number of neutralizing MAbs to the region of gB between residues 476 and 645, our studies and those of others suggest that this region is immunodominant Kniess et al., 1991 ; Liu et al., 1991; Spaete et al., 1988; Utz et al., 1989) .
Since most of the neutralizing epitopes in our panel of antibodies are dependent on the conformation of gB, the formation of the antibody recognition sites may require the juxtaposition not only of discontinuous amino acids composing those sites but also of other discontinuous I. Qadri and others residues in the amino-terminal half of gB that promote the proper folding of the antigenic domains identified in the present study. We are in the process of constructing mutant gB molecules with small deletions spanning the antigenic domains of the molecule to distinguish more precisely the amino acids that affect the epitope folding from those which are assembled into the antibody recognition site (I. Qadri & L. Pereira, unpublished data) . Preliminary analysis of the antigenic properties of these mutated forms showed that deletion of residues 170 to 411 and of residues 411 to 447 precludes assembly of domain D1 epitopes. This finding shows that amino acids 170 to 411 also play a role in assembling these epitopes. In addition, domain D3 was perturbed by deleting residues 411 to 447, which supports our finding that folding of the carboxy-terminal half of gB depends on certain residues in the amino-terminal half of the molecule. Epitopes in domain D3 are lost when residues 548 to 618 are deleted, suggesting that adjacent residues participate in the antigenic structure of this region. No antigenic changes were induced by deleting residues 645 to 702, suggesting that this region is not directly involved in assembling epitopes in the extracellular region of gB, as indicated in the present study. We recently carried out a detailed analysis of the neutralizing activities of complement-independent antibodies to CMV gB, which revealed that they prevent virion entry by blocking fusion of the viral envelope with the cell membrane, the spread of infection from cell to cell, and the formation of syncytia by infected glioblastoma cells (D. Navarro et al., unpublished data) . The detailed mutational analysis of CMV gB now underway will enable us to formulate a model for the folding of the molecule that is consistent with its antigenic structure and its function in virion infectivity and the cell-to-cell transmission of infection.
